Barrett Katz's most recent trade in Viridian Therapeutics Inc was a trade of 108,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 8, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 108,000 | 108,000 | - | - | Stock Option (Right to Buy) | |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 24,853 | 267,000 | - | - | Stock Option (Right to Buy) | |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.21 per share. | 13 Jan 2023 | 24,853 | 0 (0%) | 0% | 37.2 | 924,780 | Common Stock |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.03 per share. | 13 Jan 2023 | 24,853 | 24,853 (0%) | 0% | 23.0 | 572,365 | Common Stock |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.01 per share. | 13 Jan 2023 | 4,147 | 0 (0%) | 0% | 37.0 | 153,480 | Common Stock |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 4,147 | 291,853 | - | - | Stock Option (Right to Buy) | |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.03 per share. | 13 Jan 2023 | 4,147 | 4,147 (0%) | 0% | 23.0 | 95,505 | Common Stock |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2023 | 47,377 | 296,000 | - | - | Stock Option (Right to Buy) | |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.30 per share. | 09 Jan 2023 | 47,377 | 0 (0%) | 0% | 35.3 | 1,672,408 | Common Stock |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.03 per share. | 09 Jan 2023 | 47,377 | 47,377 (0%) | 0% | 23.0 | 1,091,092 | Common Stock |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.04 per share. | 09 Jan 2023 | 12,623 | 0 (0%) | 0% | 33.0 | 417,064 | Common Stock |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2023 | 12,623 | 343,377 | - | - | Stock Option (Right to Buy) | |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.03 per share. | 09 Jan 2023 | 12,623 | 12,623 (0%) | 0% | 23.0 | 290,708 | Common Stock |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
Viridian Therapeutics Inc | Barrett Katz | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2021 | 356,000 | 356,000 | - | - | Employee Stock Option (right to buy) |